Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. 

5AM Ventures

OrbiMed

Roche Venture Fund

Surveyor Capital

Boxer Capital

Janus Henderson Investors

Logos Capital

Cormorant Asset Management

Enliven Therapeutics

#DYK: Approximately 20% of people with CML switch therapy within the 1st year of treatment and up to 40% switch in the first 5 years of treatment. The majority of treatment switches occur early in the patient’s treatment course due to intolerance or lack and/or loss of molecular response. Join us on April 11th, to learn more about ELVN-001, our candidate for the treatment of CML: https://bit.ly/4cyFSP4

#DYK: Thanks to medical advancements, the number of patients living with #CML has more than doubled since the introduction of BCR-ABL TKIs, however, tolerability, safety, resistance and patient convenience concerns have become more prominent as patients can now expect to live on therapy for decades. Learn more: https://bit.ly/4afJ3cP 

We will be hosting a Virtual company event with KOLs on Thursday, 4/11, to discuss ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in #CML, and how ELVN-001 could fit into the CML landscape. Register here: https://bit.ly/4cyFSP4


#ICYMI: Yesterday we announced a $90M financing. We appreciate the support of our existing and new investors. This capital will help us continue to drive towards our goal of helping people with cancer to not only live longer, but live better. For more information, read the press release here: https://bit.ly/3TqPSkz 

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress. Learn more here: https://bit.ly/3Ve4whJ

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue						297K -
gross profit						-297K -
selling and marketing expenses
general and administrative expenses	2.44M -	5.11M 109.47%	1.08M 78.89%	4.29M 297.77%	7.77M 81.18%	18.95M 143.98%
selling general and administrative expenses	2.44M -	5.11M 109.47%	1.08M 78.89%	4.29M 297.77%	7.77M 81.18%	18.95M 143.98%
research and development expenses	8.24M -	19.01M 130.72%	8.24M 56.65%	20.47M 148.47%	31.02M 51.52%	64.28M 107.20%
other expenses			-9.68M -
cost and expenses	10.68M -	24.12M 125.87%	9.32M 61.36%	24.76M 165.74%	38.79M 56.66%	83.53M 115.33%
operating expenses	10.68M -	24.12M 125.87%	9.32M 61.36%	24.76M 165.74%	38.79M 56.66%	83.23M 114.57%
interest expense					-1.22M -
ebitda	-11.34M -	-23.43M 106.67%	-9.27M 60.42%	-24.65M 165.79%	-38.58M 56.51%	-83.23M 115.76%
operating income	-10.68M -	-24.12M 125.87%	-9.32M 61.36%	-24.76M 165.74%	-38.79M 56.66%	-83.53M 115.33%
depreciation and amortization	-660K -	33K 105%	45K 36.36%	115K 155.56%	215K 86.96%	297K 38.14%
total other income expenses net	-660K -	653K 198.94%	-9.65M 1,577.49%	22K 100.23%	1.13M 5,031.82%	11.95M 958.02%
income before tax	-11.34M -	-23.46M 106.96%	-18.97M 19.17%	-24.74M 30.44%	-37.66M 52.23%	-71.58M 90.07%
income tax expense		653K -	-31K 104.75%	-22K 29.03%	88K 500%
net income	-11.34M -	-23.46M 106.96%	-18.93M 19.30%	-24.72M 30.54%	-37.75M 52.72%	-71.58M 89.63%
weighted average shs out	9.44M -	9.44M 0%	41.10M 335.20%	41.10M 0%	26.29M 36.04%	35.55M 35.22%
weighted average shs out dil	9.44M -	9.44M 0%	41.10M 335.20%	41.10M 0%	26.39M 35.80%	35.55M 34.72%
eps	-1.20 -	-2.48 106.67%	-0.46 81.45%	-0.60 30.43%	-1.44 140%	-2.01 39.58%
epsdiluted	-1.20 -	-2.48 106.67%	-0.46 81.45%	-0.60 30.43%	-1.43 138.33%	-2.01 40.56%

COM:ENLIVENTHERAPEUTICS

Enlivex Therapeutics Ltd.

Last Close

25.41

22/11 21:00

Market Cap

1.08B

Beta: -

Volume Today

254.16K

Avg: -

Preview